The SORBS2 (sorbin and SH3 domain-containing protein 2) antibody is a tool used to detect and study the SORBS2 protein, encoded by the *SORBS2* gene in humans. SORBS2. also known as ArgBP2. belongs to the SORBS family of adaptor proteins characterized by conserved sorbin homology (SoHo) and multiple SH3 domains. These structural features enable SORBS2 to interact with various signaling molecules, cytoskeletal components, and membrane-associated proteins, playing roles in cell adhesion, migration, and intracellular signaling pathways. SORBS2 is particularly noted for its involvement in regulating actin dynamics, neuromuscular junction organization, and processes linked to cancer progression, such as epithelial-mesenchymal transition (EMT).
Research using SORBS2 antibodies has highlighted its tissue-specific expression, with high levels observed in cardiac and skeletal muscles, brain, and certain epithelial tissues. The protein’s dysregulation has been associated with pathological conditions, including cardiomyopathies, muscular dystrophies, and metastatic cancers. Antibodies targeting SORBS2 are essential for techniques like Western blotting, immunohistochemistry, and immunofluorescence, enabling researchers to analyze its expression patterns, subcellular localization, and interactions with binding partners (e.g., vinculin, c-Abl, and ubiquitin ligases). Validation of SORBS2 antibodies typically involves confirming specificity through knockout controls or siRNA-mediated knockdown. Commercially available antibodies are often raised against epitopes within its unique N-terminal or C-terminal regions to avoid cross-reactivity with homologous family members like SORBS1. These reagents contribute significantly to studies exploring SORBS2’s functional diversity in health and disease.